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Abstract: The first report of an iminoquinone of imidazo[4,5-f ]benzimidazole is described.
The 2D-NOESY spectrum of 1,2,3,4,8,9,10,11-octahydropyrido[1,2-a]pyrido[1’,2’:1,2]imidazo
benzimidazol-6-amine was used to confirm the location of the imine moiety at the C-6 position of the
title compound. Cytotoxicity data from the National Cancer Institute are included.
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1. Introduction
NAD(P)H:quinone oxidoreductase 1 (NQO1), also known as DT-diaphorase, is an enzyme
responsible for detoxification and bioreduction of quinone prodrugs to give hydroquinone [1].
Imidazobenzimidazoles can exist in either the 4,5-f or 5,4-f arrangement, and the Skibo
group was the first to report anti-tumour activity for five- and six-membered ring-fused
imidazo[4,5-f ]benzimidazolequinones (e.g., 1, Figure 1) [2,3]. Computational docking into the
NQO1 active site rationalized differential cytotoxicity of imidazo[4,5-f ]benzimidazolequinones [3].
Our group provided synthetic routes to enable efficient access to both 4,5-f and 5,4-f
imidazobenzimidazolequinones [4–6].
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Figure 1. Rational drug design: targeting of iminoquinone 3 based on reported NAD(P)H:quinone 
oxidoreductase 1 (NQO1) substrates. 
Iminoquinone 2 was unexpectedly isolated en route to the imidazo[5,4-f]benzimidazolequinone 
(see below) [4], and found to have exceptional and variable cytotoxicity against the 60 human cell 
lines of the developmental therapeutics program (DTP) at the National Cancer Institute (NCI) [6].  
NCI COMPARE analysis and computational docking of 2 gave moderate compatibility to human 
NQO1. We now disclose novel isomeric iminoquinone 3, synthesis, spectroscopic characterization, 
and cytotoxicity at DTP-NCI. 
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2. Results and Discussion
2.1. Synthesis
The multi-step synthesis described by Fagan and Aldabbagh for imidazo[5,4-f ]
benzimidazolequinones was modified to give 6-imino-1,2,3,4,8,9,10,11-octahydropyrido
pyrido[1′,2′:1,2]imidazo[4,5-f ]benzimidazole-13-one (3) (Scheme 1) [5]. The first four steps
furnished imidazo[4,5-f ]benzimidazole 4, in an overall yield of 51% without the characterization
of reaction intermediates. Nitric and sulfuric acid (1:1 mixture) were used in the nitration
of 4 to give 6-nitroimidazo[4,5-f ]benzimidazole 5 in a 54% yield, alongside trace amounts
of the 13-nitro and dinitro isomers, which were discarded after column chromatography.
Atmospheric-pressure catalytic hydrogenation gave the novel aromatic amine 1,2,3,4,8,9,10,11-
octahydropyrido[1,2-a]pyrido[1’,2’:1,2]imidazo[4,5-f ]benzimidazol-6-amine (6), in an almost
quantitative yield of 96%. The regioselectivity of the nitration/reduction to give 6 was determined
from the 2D NOESY spectrum with through-space 1H-1H coupling of the aromatic 13-H to 1-CH2 and
11-CH2 of 6 (Figure 2).
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separate environments. Further investigations were limited by the sparing solubility of 3 in CDCl3, 
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(KHSO5·0.5KHSO4·0.5K2SO4), AcOH, 40 ◦C, 7 h.
Iminoquinone 2 was previously obtained by Frémy salt (K2NO(SO3)2) oxidation of the aromatic
amine precursor at pH 4 [4]. Under the same buffered conditions, amine 6 gave only the undesired
quinone 1, as a result of acidic hydrolysis. Carrying out the Frémy oxidation at neutral pH, however,
formed the desired iminoquinone 3 in 61% yield, along with quinone 1, separated by column
chromatography in 8% yield. For isolated 3, the triplet at 4.31 ppm in the 1H NMR, and the peaks at
151.3, 142.4 and 130.2 p m in the 13C NMR arise from the presence of minor quantities of quinone
1 [4], which for ed upon acidic hydrolysis of the i i oquinone on silica gel using ’conventional’
column c ro atography (see NMR spectra in Supplementary Materials). Deacti ating the silica with
triethylamine prior to elution gave spectroscopically pure compound 3, in an improved yield of 67%,
along with quinone 1 in a 6% yield. The imine group of 3 was observed, with N-H at ~11 ppm in
the 1H NMR spectrum, and C=N at 157 ppm in the 13C NMR spectrum, in accordance with reported
data for iminoquinone 2 [4]. It is noteworthy that the non-equivalence of CH2 signals for the fused
pyrido-rings of 3 are not observed in the NMR spectra, presumably due to the greater rates of exchange
of the N-H signals in comparison to the NMR frequency difference of the proton resonances in the
separate environments. Further investigations were limited by the sparing solubility of 3 in CDCl3,
with the NMR spectra taken at the compound’s solubility limit (see Supplementary Materials).
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2.2. Cytotoxicity
The cytotoxicity of iminoquinone 3 was evaluated at the DTP-NCI, USA [2,6,7]. One-dose
testing at 10 µM concentration against the 60-cancer cell line panel showed negligible cytotoxicity
(see Supplementary Materials). This is in contrast to isomeric iminoquinone 2, which displayed
significant cytotoxicity against several solid tumour cell lines [6], and was selected for subsequent five
dose testing. Given the low toxicity, no further biochemical assays and computational docking studies
were carried out on iminoquinone 3.
3. Materials and Methods
3.1. Materials and Measurements
Piperidine (Sigma Aldrich, 99%, St. Louis, MO, US ), NaHCO3 (Fisher Scientifi , ≥99.7%,
Waltham, MA, USA), 1,5-difluoro-2,4-dinitrobenzene (Sigma Aldrich, 97%), Pd-C (Sigma Aldrich,
10 wt% loading), EtOAc (VWR, 99.9%), Ac2O (ACROS Organics™, 99+%), AcOH (VWR, glacial),
Oxone (Sigma Aldrich, KHSO5·0.5KHSO4·0.5K2SO4), Na2CO3 (Fisher Scientific, 99.5%), CH2Cl2 (Fisher
Scientific, 99.8%), HNO3 (Fisher Scientific, 70%), H2SO4 (Fisher Scientific, ≥95%), MeOH (VWR,
≥99.8%) and potassium nitrosodisulfonate (Sigma Aldrich) were used as received. THF was freshly
distilled over Na and benzophenone prior to use. Thin layer chromatography (TLC) was performed
on TLC silica gel 60 F254 plates. ’Conventional’ flash c lumn chromatography was carried out on
silica gel (Ap llo Scientific 60/40−63 µm), and d activat by making a slurry using Et3N in EtOAc
(2% v/v), for the purification of title compound 3. Melting points were mea ured on a Stuart Scientific
melting point apparatus SMP1. IR spectra were recorded using a PerkinElmer Spec 1 with ATR
(Perkin-Elmer, Waltham, MA, USA) attached. NMR spectra were recorded using a Bruker Avance
II 400 MHz spectrometer (Bruker Corporation, Billerica, MA, USA). The chemical shifts are in ppm,
relative to tetramethylsilane. 13C NMR spectra at 100 MHz are with complete proton decoupling. NMR
assignments are supported by distortionless enhancement by polarization transfer (DEPT). The HRMS
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spectrum of iminoquinone 3 was obtained at the National University of Ireland Galway, using an ESI
time-of-flight mass spectrometer (TOFMS) on a Waters LCT Mass Spectrometry instrument, while
the HRMS spectrum of aromatic amine 6 was obtained at the National Mass Spectrometry Facility at
Swansea University using a Waters Xevo G2-S mass spectrometer (Waters, Milford, MA, USA) with an
atmospheric solids analysis probe (ASAP). The precision of all accurate mass measurements was better
than 5 ppm.
3.2. Synthetic Procedures
3.2.1. Synthesis of 1,2,3,4,8,9,10,11-Octahydropyrido[1,2-a]pyrido[1’,2’:1,2]imidazo[4,5-f ]
benzimidazole (4)
Piperidine (7.50 mL, 75.9 mmol), NaHCO3 (4.210 g, 50.1 mmol) and 1,5-difluoro-2,4-dinitrobenzene
(2.042 g, 10.0 mmol) in THF (80 mL) were stirred at room temperature for 1 h. Water (200 mL) was
added and the precipitate was collected, washed with water and dried. The yellow solid was stirred
with Pd-C (0.206 g) in EtOAc (100 mL) under an atmosphere of H2 (1 atm; balloon) for 16 h. Upon
filtering the solution through Celite and evaporating the filtrate to dryness, Ac2O (9.45 mL, 0.100 mol)
and AcOH (100 mL) were added, and the solution was stirred at 80 ◦C for 30 min. The mixture was
evaporated, NaHCO3 (5% aq, 150 mL) was added, and the mixture was stirred for 1 h. The precipitate
was collected, washed with water, and re-dissolved in AcOH (80 mL). Oxone (18.225 g, 59.3 mmol)
was added, and the mixture was stirred at 40 ◦C for 7 h. The solution was evaporated, H2O (100 mL)
was added, neutralized with solid Na2CO3, and extracted with CH2Cl2 (3 × 100 mL). The organic
extracts were dried (MgSO4) and evaporated to dryness to give the title compound 4 (1.358 g, 51%),
as an off-white solid; m.p. decomp. >264 ◦C; lit. m.p. decomp. 266–270 ◦C [4]; spectral data was
consistent with the literature (Supplementary Materials) [4].
3.2.2. Synthesis of 6-Nitro-1,2,3,4,8,9,10,11-octahydropyrido[1,2-a]pyrido[1’,2’:1,2]imidazo[4,5-f ]
benzimidazole (5)
Imidazo[4,5-f ]benzimidazole 4 (0.963 g, 3.6 mmol), HNO3 (40 mL) and H2SO4 (40 mL) were
stirred at 80 ◦C for 3 h. The mixture was diluted with H2O (300 mL), neutralized with solid Na2CO3,
and extracted with CH2Cl2 (4 × 100 mL). The organic extracts were dried (MgSO4), evaporated, and
purified by column chromatography using gradient elution of EtOAc/MeOH to give the title compound
5 (0.608 g, 54%) as a yellow solid; Rf 0.29 (9:1 EtOAc/MeOH); m.p. decomp. >238 ◦C; lit. m.p. decomp.
230–232 ◦C [3]; spectral data was consistent with the literature (Supplementary Materials) [3].
3.2.3. Syntheis of 1,2,3,4,8,9,10,11-Octahydropyrido[1,2-a]pyrido[1’,2’:1,2]imidazo[4,5-f ]
benzimidazol-6-amine (6)
6-Nitroimidazo[4,5-f ]benzimidazole 5 (0.502 g, 1.6 mmol), and Pd-C (50 mg) in MeOH (100 mL)
were stirred under H2 at room temperature for 16 h. The mixture was filtered through Celite and
evaporated to dryness to give the title compound 6 (0.432 g, 96%) as an off-white solid; m.p. decomp.
>215 ◦C; νmax (neat, cm−1) 3421, 3308 (both NH2), 3237, 3205, 2951, 2936, 2877, 2864, 2831, 1694,
1683, 1630, 1596, 1532, 1513, 1484, 1456, 1439, 1426, 1385, 1345, 1324, 1283, 1255, 1218, 1164; 1H NMR
(400 MHz, CDCl3) δ: 6.40 (s, 1H), 5.04–4.56 (br.s, disappears with D2O, 2H, NH2), 4.00 (t, J = 6.1 Hz, 4H,
1,11-CH2), 3.06 (t, J = 6.4 Hz, 4H, 4,8-CH2), 2.16–2.07 (m, 4H), 2.04–1.95 (m, 4H); 13C NMR (100 MHz,
CDCl3) δ: 148.9, 133.0, 127.7, 126.4 (all C), 76.1 (CH), 42.6, 25.6, 22.8, 20.9 (all CH2); HRMS (ASAP) m/z
[M + H]+ found 282.1717, C16H20N5 requires 282.1719.
3.2.4. Frémy Oxidation of 6 to Give Title Compound 3
Potassium nitrosodisulfonate (1.012 g, 3.77 mmol) in phosphate buffer (0.2 M, pH 7, 80 mL) was
added to amine 6 (0.352 g, 1.25 mmol) in the same buffer (40 mL), and stirred at room temperature for
1 h. The mixture was extracted with CH2Cl2 (4 × 90 mL), and the organic extracts were dried (MgSO4),
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evaporated, and purified by column chromatography using a gradient elution of EtOAc/MeOH/Et3N to
give 1,2,3,4,8,9,10,11-octahydropyrido[1,2-a]pyrido[1′,2′:1,2]imidazo[4,5-f]benzimidazol-6,13-dione (1) (22 mg,
6%); orange solid; Rf 0.32 (9:1 EtOAc/MeOH); the spectral data and melting point were consistent with
the literature [4]. Further elution gave 6-imino-1,2,3,4,8,9,10,11-octahydropyrido[1,2-a]pyrido[1′,2′:1,2]
imidazo[4,5-f]benzimidazole-13-one (3) (0.248 g, 67%); yellow solid; Rf 0.21 (9:1 EtOAc/MeOH); m.p.
decomp. >225 ◦C; νmax (neat, cm−1) 2946, 1637 (C=O), 1482, 1422, 1304, 1264, 1166, 1021; 1H NMR
(400 MHz, CDCl3) δ: 11.32–10.60 (br.s, disappears with D2O, 1H, NH), 4.34 (t, J = 5.9 Hz, 4H, 1,11-CH2),
2.99 (t, J = 6.3 Hz, 4H, 4,8-CH2), 2.10–1.92 (m, 8H); 13C NMR (100 MHz, CDCl3) δ: 169.4 (C=O), 157.1
(C=N), 150.7, 142.3, 127.0 (all C), 45.3, 25.0, 22.4, 19.8 (all CH2); HRMS (ESI) m/z [M + H]+ found
296.1506, C16H18N5O requires 296.1511.
Supplementary Materials: The following are available online, 1H NMR spectrum of 1,2,3,4,8,9,10,11-
octahydropyrido[1,2-a]pyrido[1’,2’:1,2]imidazo[4,5-f ]benzimidazole (4), 1H NMR spectrum of 6-nitro-1,2,3,4,8,9,10,11-
octahydropyrido[1,2-a]pyrido[1’,2’:1,2]imidazo[4,5-f ]benzimidazole (5), 1H NMR, 13C NMR and 1H-1H
NOESY spectra of 1,2,3,4,8,9,10,11-octahydropyrido[1,2-a]pyrido[1’,2’:1,2]imidazo[4,5-f ]benzimidazol-6-amine
(6), 1H NMR and 13C NMR spectra of 6-imino-1,2,3,4,8,9,10,11-octahydropyrido[1,2-a]pyrido[1’,2’:1,2]imidazo
benzimidazole-13-one (3) after purification by ’conventional’ flash column chromatography on silica gel and
after purification by flash column chromatography on silica gel deactivated with Et3N, and DTP-NCI-60 mean
growth percent graph for 6-imino-1,2,3,4,8,9,10,11-octahydropyridopyrido[1’,2’:1,2]imidazo[4,5-f ]benzimidazole-
13-one (3).
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